NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 3 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Q2 FY27 Net Profit Rises 26% to ₹4.86 Cr; SteriPort Line 3 Expands Capacity by 75%
Amanta Healthcare reported a 17% YoY increase in Q2 FY27 revenue to ₹83.1 crore, while net profit grew 26% YoY to ₹4.86 crore with an EBITDA margin of 21.6%. SteriPort Line 3 was commissioned in early September 2026, increasing annual capacity by 75% to roughly 11.6 crore units and expected to contribute ₹60 crore to FY27 revenue. The company is also targeting ₹400-420 crore in revenue by FY28, supported by an upcoming 52% expansion in Small Volume Parenterals (SVP) in Q1 FY28. Debt-to-equity has improved to 1.1x in FY26 from 3.5x in FY23, supported by annual captive solar power cost savings of ~₹9 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுAmanta published its Q2/H1 FY27 earnings call transcript detailing the operationalization of SteriPort Line 3 and FY28 growth guidance.
ஏன் இது முக்கியம்The commissioning of SteriPort Line 3 and upcoming SVP expansion provide visible volume scale-up to support the company's 20%+ CAGR target while captive solar helps protect margins.
📅 குறுகிய காலம்Earnings commentary outlines sustained top-line momentum driven by incremental volumes from the newly commissioned SteriPort Line 3.
📈 நீண்ட காலம்Capacity expansions in high-margin SteriPort and SVP lines, coupled with international market expansion, provide operating leverage toward the ₹400+ crore FY28 target.
⚠ அபாய எச்சரிக்கைகள்
Regulatory variation filings for SVP inhalation lines can take 6-9 months, delaying full ramp-up
Annual debt servicing obligations of roughly ₹35 crore
👀 கவனிக்க வேண்டியவை
Track the ramp-up of SteriPort Line 3 to full capacity by Q3/Q4 FY27 and monitor execution timelines for the new SVP line slated for Q1 FY28.
Amanta Healthcare Q2 FY27 Revenue Up 17% to ₹83 Cr; Line 3 Boosts SteriPort Capacity 75%
Amanta Healthcare released its Q2 FY27 investor presentation, reporting revenue of ₹83.13 crore (up 17.3% YoY) and net profit of ₹4.86 crore with an EBITDA margin of 21.6%. The company commissioned SteriPort Line 3 in September 2026, expanding capacity by 75% from 6.6 crore to 11.6 crore bottles, with ~₹60 crore revenue expected from this line in FY27. Further capacity additions are slated for Q1 FY28, expanding Small Volume Parenteral (SVP) from 20.9 crore to 31.7 crore units. Balance sheet leverage has moderated, with debt-to-equity declining from 3.5x in FY23 to ~1.1x in FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுAmanta Healthcare reported strong Q2 FY27 financial performance and confirmed the successful operationalization of its SteriPort Line 3 alongside ongoing SVP expansion plans.
ஏன் இது முக்கியம்The commissioning of Line 3 and upcoming SVP expansion provide significant revenue growth visibility (targeting 20%+ CAGR), while captive solar generation and debt reduction support margin expansion and balance sheet health.
📅 குறுகிய காலம்Operational commencement of Line 3 should begin reflecting incrementally in top-line figures across H2 FY27, supported by reduced operating costs from the captive solar plant.
📈 நீண்ட காலம்The shift toward high-margin SteriPort lines and specialty SVP products positions the business to achieve its stated targets of 20%+ revenue CAGR and 25%+ EBITDA margins over the next two years.
⚠ அபாய எச்சரிக்கைகள்
Execution and utilization risk for newly added capacities
Sensitivity to crude oil-linked raw material (plastic granules) prices
Sizable current borrowings of ₹147 crore as of H1 FY27
👀 கவனிக்க வேண்டியவை
Track the ramp-up and margin delivery of SteriPort Line 3 over upcoming quarters and monitor progress toward the Q1 FY28 operational timeline for the SVP expansion.
Amanta Q2FY27 PAT Jumps to ₹4.86 Cr; SteriPort Capacity Raised 75%
Amanta Healthcare reported a 17.3% YoY rise in Q2FY27 revenue to ₹83.13 crore, driven by price increases and contributions from new capacity. EBITDA grew 21.9% YoY to ₹17.95 crore, with operating margin expanding ~80 bps to 21.6%. Net profit climbed to ₹4.86 crore compared to ₹1.21 crore in Q2FY26 (which included a ₹2.63 crore exceptional item). In early September 2026, the company commissioned SteriPort Line 3, expanding bottle capacity by 75% to 11.6 crore bottles and targeting ₹60 crore incremental revenue in FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுAmanta reported strong Q2FY27 financial results and officially commissioned its SteriPort Line 3 expansion.
ஏன் இது முக்கியம்The commissioning of Line 3 expands high-margin SteriPort capacity by 75%, generating expected annual revenue of ₹110–120 crore at optimal utilisation alongside ~₹9 crore annual energy savings from captive solar.
📅 குறுகிய காலம்Market sentiment should react positively to the 17% topline growth, margin expansion, and operational commissioning of the SteriPort line.
📈 நீண்ட காலம்Structural transformation underway as higher-margin SteriPort and upcoming Q1FY28 SVP expansions increase operating leverage and expand market reach.
⚠ அபாய எச்சரிக்கைகள்
Finance costs rose 13.4% YoY to ₹5.84 crore reflecting debt servicing on capex
Raw material vulnerability to crude oil price swings impacting packaging costs
👀 கவனிக்க வேண்டியவை
Track the ramp-up and capacity utilisation of SteriPort Line 3 in H2FY27 and the progress toward the upcoming SVP capacity expansion targeted for Q1FY28.
Amanta Healthcare COO Anil Rathi Resigns Effective October 29, 2026
Amanta Healthcare Limited announced the resignation of its Chief Operating Officer (COO), Shri Anil Rathi, effective October 29, 2026. The departure was cited as a resignation pursued for better career opportunity and personal growth. As a Senior Management Personnel, the COO plays a key role in manufacturing and operational delivery across its Kheda facilities. The company has not yet announced an interim or permanent successor for the role.
உச்சம் நம்பிக்கை
என்ன மாறியதுChief Operating Officer Anil Rathi has stepped down from his executive position effective October 29, 2026.
ஏன் இது முக்கியம்The COO oversees core manufacturing and supply chain operations; an abrupt vacancy can affect operational continuity during an ongoing capex cycle.
Resignation effective date: அக்டோபர் 29, 2026Announcement filing date: அக்டோபர் 30, 2026
📅 குறுகிய காலம்Neutral to mild watch as operations transition and leadership continuity is addressed.
📈 நீண்ட காலம்Limited structural impact assuming the company swiftly appoints a qualified replacement to manage plant operations.
⚠ அபாய எச்சரிக்கைகள்
Key management transition risk
Operational disruption risk during capacity expansion phase
👀 கவனிக்க வேண்டியவை
Track the appointment of a new Chief Operating Officer to ensure no disruption in the ongoing Rs 90 Cr Steriport expansion and operational ramp-up.
Amanta Healthcare Commissions New SteriPort Line at Kheda Facility
Amanta Healthcare Limited has announced the commencement of commercial production at its new brownfield SteriPort facility located at its Kheda campus in Gujarat. The new automated line produces two-port IV containers designed for oncology and intensive care formulations with higher container integrity and reduced human intervention. The expansion is aimed at scaling operational efficiency and driving EBITDA margin expansion through higher-margin specialty parenteral products. This marks the operationalization of the company's core strategic growth driver, previously flagged as part of its INR 90 Cr SteriPort expansion program.
உச்சம் நம்பிக்கை
என்ன மாறியதுAmanta Healthcare transitioned its new SteriPort line at the Kheda facility from development to active commercial production.
ஏன் இது முக்கியம்The SteriPort segment commands higher negotiating power and margins compared to standard LVP/SVP lines, directly supporting the company's strategy to expand operating profitability.
📅 குறுகிய காலம்Positive sentiment as a key capital project is successfully commissioned without reported delays.
📈 நீண்ட காலம்Enhances the product mix toward higher-margin sterile injectables and oncology solutions, strengthening export capabilities and margin resilience.
⚠ அபாய எச்சரிக்கைகள்
Ramp-up timeline and capacity utilization rates post-commissioning
Raw material price volatility (crude-derived plastic granules) affecting container packaging costs
👀 கவனிக்க வேண்டியவை
Track capacity ramp-up and margin trajectory in upcoming quarterly financial results to evaluate the revenue and EBITDA contribution from the new SteriPort line.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Amanta Healthcare targets ₹120 cr peak revenue from new SteriPort line; production starts Aug 2026
Amanta Healthcare reported Q1 FY27 revenue of ₹69 cr, a 5% YoY growth, with EBITDA margins holding steady at 22% despite inflationary pressures. The company's ₹90 cr SteriPort expansion is nearing completion, with commercial production on Line 3 expected by late August 2026 after a one-quarter delay. This new line is projected to add ₹110-120 cr to the annual top line, nearly doubling SteriPort capacity to 12 crore bottles. Additionally, a 10.8 MW solar plant commissioned in June 2026 is expected to save ₹9 cr annually, supporting a targeted 4-5% EBITDA margin expansion.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company confirmed a revised timeline for its SteriPort expansion (delayed from Q1 to Q2 FY27) and provided specific revenue and margin guidance for the new capacity.
ஏன் இது முக்கியம்The ₹90 cr capex is highly material compared to current quarterly revenues (~₹69 cr), and the shift toward high-value SteriPort products (currently 44% of revenue) is critical for long-term margin improvement.
📅 குறுகிய காலம்The stock may react positively to the concrete timeline for commercial production (late August 2026) and the expected margin benefits from the already-commissioned solar plant.
📈 நீண்ட காலம்Structural shift towards higher-margin specialty products and lower energy costs could permanently re-rate the company's profitability profile over the next 2-3 years.
⚠ அபாய எச்சரிக்கைகள்
Execution risk on the delayed SVP facility (Q4 FY27)
Sensitivity to crude oil prices affecting polymer costs
High dependence on short-term debt for working capital
👀 கவனிக்க வேண்டியவை
Watch for the successful commercial ramp-up of SteriPort Line 3 in late August 2026 and the subsequent impact on Q2 FY27 margins to validate the 4-5% expansion guidance.
Amanta Healthcare Q1 FY27: Revenue at ₹69.45 Cr (up 4.8% YoY), PAT down 5.6% to ₹3.31 Cr
Amanta Healthcare reported a modest 4.8% YoY increase in total income from operations to ₹69.45 crore for the quarter ended June 30, 2026. However, net profit after tax declined by 5.6% YoY to ₹3.31 crore, down from ₹3.51 crore in the same period last year. Earnings per share (EPS) consequently fell to ₹0.85 from ₹1.22. The results indicate slight margin pressure as profit contracted despite the marginal revenue growth.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has released its unaudited financial results for the first quarter of FY27, showing marginal top-line growth but a decline in profitability.
ஏன் இது முக்கியம்The results reflect the company's performance in a competitive parenteral business environment; the decline in PAT despite higher revenue suggests rising operating costs or pricing pressure.
Total Income (Q1 FY27): ₹69.45 கோடிNet Profit (Q1 FY27): ₹3.31 கோடிYoY Revenue Growth: 4.8%YoY PAT Growth: -5.6%Q1 Revenue vs FY26 Revenue: 23.86%
📅 குறுகிய காலம்The stock may remain range-bound or see slight pressure due to the year-on-year decline in net profit and EPS.
📈 நீண்ட காலம்Long-term value depends on the successful ramp-up of high-value Steriport products and international market expansion to improve margins.
⚠ அபாய எச்சரிக்கைகள்
Margin compression (PAT down despite revenue growth)
Low pricing power in LVP/SVP segments
Intense competition in the parenteral business
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the ₹90 crore Steriport capacity expansion, as current revenue growth (4.8%) is trailing the company's long-term target of 8-10%.
5.4% Revenue Growth in Q1FY27; ₹90 Cr Capacity Expansion on Track for Q2 Commissioning
Amanta Healthcare reported a steady Q1FY27 with revenue growing 5.4% YoY to ₹68.80 cr, driven by improved product mix. However, EBITDA margins compressed by 200 bps to 22% due to higher raw material and employee costs. PAT declined 5.6% YoY to ₹3.31 cr, primarily impacted by increased finance costs from a new solar term loan. The company confirmed that its Steriport plant is on track for Q2FY27 commissioning, which is a key trigger for future growth.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from the planning phase to the final commissioning phase of its Steriport expansion while managing slight margin pressure from operational costs.
ஏன் இது முக்கியம்The ₹90 cr capex is significant relative to the company's current revenue scale; successful execution will shift the product mix toward higher-value specialty segments like Steriport.
📅 குறுகிய காலம்The stock may see neutral to slightly cautious sentiment due to the margin dip and PAT decline, despite the revenue growth.
📈 நீண்ட காலம்The structural story depends on the ₹90 cr expansion; if the Steriport and SVP lines ramp up as planned by FY27-end, it could significantly re-rate the earnings profile.
⚠ அபாய எச்சரிக்கைகள்
Margin compression from raw material volatility
Rising finance costs impacting net profitability
Execution risk on the remaining SVP expansion timeline
👀 கவனிக்க வேண்டியவை
Watch for the successful commissioning and utilization levels of the Steriport facility in the next quarterly update, as this capacity is critical for margin expansion.
Amanta Healthcare Targets 20%+ Revenue CAGR; Commissioning Major Capacity in FY27
Amanta Healthcare has outlined a significant growth roadmap in its Q1FY27 presentation, targeting a 20%+ revenue CAGR and 25%+ EBITDA margins. The company is in the final stages of a major capacity expansion, adding 5.39 Cr SteriPort units and 10.78 Cr SVP units with commissioning expected in Q2 and Q4 of FY27. Financial health has improved with the debt-to-equity ratio dropping from 3.50x in FY23 to 1.06x in FY26. Additionally, a 10.8 MW solar plant is expected to generate annual savings of ₹9 Cr, directly impacting the bottom line.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has provided a concrete timeline for its capacity commissioning and formalized aggressive margin and growth targets for the next cycle.
ஏன் இது முக்கியம்The shift toward high-margin SteriPort (ISBM technology) and cost-saving solar energy represents a structural move to improve profitability and pricing power in the parenteral segment.
SteriPort Capacity Addition: 5.39 Cr unitsSVP Capacity Addition: 10.78 Cr unitsExpected Solar Savings: ₹9 Cr per annumDebt-to-Equity (FY26): 1.06xCWIP vs FY26 Revenue: ~125%
📅 குறுகிய காலம்The market is likely to react positively to the clear commissioning timelines and the substantial reduction in debt levels.
📈 நீண்ட காலம்If the company achieves its 25% EBITDA margin target through specialty products and energy savings, it could lead to a significant re-rating of the stock.
⚠ அபாய எச்சரிக்கைகள்
Execution risk for the new production lines
Volatility in crude oil prices affecting plastic granule costs
👀 கவனிக்க வேண்டியவை
Investors should track the successful commissioning of the SteriPort expansion in Q2FY27 and the SVP expansion in Q4FY27 to validate the projected 20% growth trajectory.
Amanta Healthcare Approves Q1 FY27 Results; 31st AGM Set for Sept 16, 2026
Amanta Healthcare's board has approved the financial results for the quarter ended June 30, 2026, with an unmodified audit opinion. The company has scheduled its 31st Annual General Meeting (AGM) for September 16, 2026. Additionally, the board dissolved the IPO Committee, which was originally formed in August 2024, signaling the completion of its specific mandate. These developments follow a fiscal year (FY26) where the company reported revenue of ₹65.31 crore and a PAT of ₹3.51 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has finalized its Q1 FY27 performance review and set the timeline for its annual shareholder meeting, while formally ending the tenure of its IPO oversight committee.
ஏன் இது முக்கியம்The meeting confirms the company's transition into a post-IPO phase and provides the schedule for shareholder engagement. The dissolution of the IPO committee suggests administrative processes related to the listing are concluded.
FY26 Revenue: ₹65.31 கோடிPlanned Capex: ₹90 கோடிCapex vs FY26 Revenue: 137.8%AGM Date: செப்டம்பர் 16, 2026
📅 குறுகிய காலம்The stock may see routine movement as investors digest the Q1 results and the upcoming AGM details.
📈 நீண்ட காலம்The structural focus remains on the ₹90 crore Steriport expansion and the company's ability to scale high-value products in international markets like Cambodia and Zimbabwe.
⚠ அபாய எச்சரிக்கைகள்
High dependence on short-term debt
Sensitivity to crude oil prices affecting plastic granule costs
Low pricing power in LVP/SVP segments due to NPPA regulations
👀 கவனிக்க வேண்டியவை
Investors should review the detailed Q1 FY27 financial statements once published to assess if the 8-10% growth target is being met and track the progress of the ₹90 crore Steriport expansion.
Amanta Healthcare Promoter Bhavesh Patel Acquires Shares via Open Market
Amanta Healthcare Limited has informed the exchanges that Shri Bhavesh Girishbhai Patel, a member of the promoter group, has purchased equity shares of the company from the open market. The disclosure was made on June 22, 2026, in compliance with Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. Such open-market purchases by promoters are typically viewed as a sign of confidence in the company's current valuation and future growth prospects.
முக்கிய அம்சங்கள்
Promoter Bhavesh Girishbhai Patel executed an open-market purchase of equity shares.Disclosure filed under SEBI (Prohibition of Insider Trading) Regulations, 2015.The transaction was officially reported to BSE and NSE on June 22, 2026.Insider buying often signals that management believes the stock is undervalued or expects positive developments.
👀 கவனிக்க வேண்டியவை
Investors should take this as a positive signal of promoter confidence, though they should also monitor the upcoming quarterly shareholding pattern to see the exact percentage increase in promoter stake.
Promoter Bhavesh Girishbhai Patel Acquires Shares of Amanta Healthcare via Open Market
Amanta Healthcare Limited has informed the exchanges that Shri Bhavesh Girishbhai Patel, a member of the promoter group, has purchased equity shares of the company through the open market. The disclosure was filed on June 18, 2026, under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. Such open-market purchases by promoters are generally viewed as a sign of confidence in the company's long-term value and future prospects.
முக்கிய அம்சங்கள்
Promoter Shri Bhavesh Girishbhai Patel purchased equity shares via the open market.Disclosure submitted in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.The notification was officially recorded by the company on June 18, 2026.The transaction involves Amanta Healthcare Limited (BSE: 544502, NSE: AMANTA).
👀 கவனிக்க வேண்டியவை
Investors should monitor the specific quantity and price of shares purchased in the detailed Form C filing to gauge the strength of the promoter's conviction. Promoter buying is typically a bullish indicator for the stock.
Amanta Healthcare Commissions 10.8 MWp Solar Power Plant for Captive Consumption
Amanta Healthcare Limited has successfully commissioned a 10.8 MWp solar power plant located in Kheda, Gujarat. The facility is designed for captive consumption, which is expected to significantly reduce the company's electricity expenses and overall operational costs. All necessary regulatory approvals have been secured, and power generation officially commenced on May 30, 2026. This initiative enhances the company's sustainability profile while potentially improving operating margins over the long term.
முக்கிய அம்சங்கள்
Successfully commissioned a 10.8 MWp solar power plant in Village Baroda, Kheda district.The plant is dedicated to captive consumption to lower operational and energy costs.Power generation and operations officially started on May 30, 2026.All requisite regulatory approvals for the project have been received.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's upcoming quarterly financial results to quantify the reduction in power and fuel expenses and the resulting impact on EBITDA margins.
Amanta Healthcare Reports Zero Deviation in ₹126 Crore IPO Fund Utilization for Q4 FY26
Amanta Healthcare Limited has confirmed that there were no deviations or variations in the utilization of the ₹126 crore raised through its IPO in September 2025. As of March 31, 2026, the company has deployed ₹47.66 crore toward setting up a new manufacturing line for SteriPort in Kheda, Gujarat. Notably, actual issue expenses were ₹22.85 crore, which was ₹3.58 crore higher than initially estimated, resulting in a corresponding reduction in the budget for General Corporate Purposes. No funds have been utilized yet for the Small Volume Parenterals (SVP) manufacturing line project.
முக்கிய அம்சங்கள்
Total IPO proceeds of ₹126 crore raised with zero reported deviation from the objects of the issue.₹47.66 crore utilized for the SteriPort manufacturing line against a total allocation of ₹70 crore.Actual issue expenses reached ₹22.85 crore, exceeding the initial estimate of ₹19.26 crore by ₹3.58 crore.General Corporate Purposes allocation was revised downward to ₹3.02 crore to offset higher issue costs.The ₹30.13 crore allocation for the SVP manufacturing line remains unutilized as of the quarter ended March 2026.
👀 கவனிக்க வேண்டியவை
Investors should track the execution timeline of the SteriPort and SVP manufacturing lines, as these capacity expansions are critical for future revenue growth. The lack of deviation indicates disciplined financial management of IPO proceeds.
Amanta Healthcare FY26 PAT Jumps 42% to ₹15 Cr; Capacity Expansion to 12 Cr Bottles Underway
Amanta Healthcare reported a robust FY26 performance with revenue reaching INR 288 crores and a significant 42% growth in PAT to INR 15 crores. The company is nearly doubling its SteriPort capacity from 6.6 crore to 12 crore bottles per year to meet rising demand in critical care and oncology. Operational efficiency is expected to improve further with the commissioning of a 10.8 MW captive solar plant and a strengthened balance sheet where the debt-to-equity ratio has improved from 3x to 1x.
முக்கிய அம்சங்கள்
FY26 Revenue grew 5% to INR 288 crores with EBITDA margins stable at 22% (INR 63 crores)Full-year PAT increased by 42% YoY to INR 15 crores, while Q4 PAT rose 28% to INR 5.5 croresSteriPort capacity is expanding from 6.6 crore to 12 crore bottles per year, with commissioning expected next monthDebt-to-equity ratio significantly improved from 3x to 1x over the last three yearsA 10.8 MW captive solar power project is set for commissioning within days to reduce energy costs from FY27
👀 கவனிக்க வேண்டியவை
Investors should monitor the ramp-up of the new SteriPort capacity and the resulting operating leverage in FY27. The company's successful deleveraging and focus on high-value segments like inhalation and ophthalmics provide a strong foundation for long-term growth.
Amanta Healthcare Approves FY26 Financial Results and Updates Governance Policies
Amanta Healthcare Limited announced the approval of its financial results for the quarter and full year ending March 31, 2026, during its board meeting on May 19, 2026. The company's statutory auditors, Price Waterhouse Chartered Accountants LLP, issued an unmodified opinion, confirming the reliability of the financial statements. Furthermore, the board approved revisions to the Code of Conduct for Prevention of Insider Trading and the Whistle Blower Policy. These administrative updates are aimed at strengthening internal controls and maintaining high standards of corporate governance.
முக்கிய அம்சங்கள்
Board approved standalone financial results for the quarter and year ended March 31, 2026Statutory auditors Price Waterhouse Chartered Accountants LLP issued an unmodified audit opinionRevision of the Code of Conduct for Prevention of Insider Trading approved by the boardWhistle Blower Policy updated to enhance corporate governance frameworksThe board meeting concluded within approximately 3 hours (12:15 PM to 03:10 PM)
👀 கவனிக்க வேண்டியவை
Investors should review the detailed financial statements on the company's website to assess specific growth metrics for FY26. The unmodified audit opinion and policy updates indicate a stable regulatory and governance environment.
Amanta Healthcare FY26 PAT Surges 42% to ₹14.88 Cr; Q4 Revenue Up 7%
Amanta Healthcare reported a steady FY26 with revenue growing 4.7% to ₹287.68 crore and a significant 41.7% jump in Net Profit to ₹14.88 crore. The bottom-line growth was primarily driven by reduced finance costs and improved operating leverage, despite a slight dip in Q4 EBITDA margins from 24% to 22%. The company is currently undergoing major capacity expansions in its SteriPort and SVP segments to drive future growth. Management remains focused on high-margin products and operational efficiencies through a new captive solar project.
முக்கிய அம்சங்கள்
FY26 Net Profit increased by 41.7% YoY to ₹14.88 crore, with PAT margins improving from 4% to 5%.Annual Revenue grew 4.7% YoY to ₹287.68 crore, while Q4 revenue rose 6.8% to ₹76.99 crore.Q4 PAT saw a 28% YoY increase to ₹5.53 crore, supported by lower finance costs and operational discipline.FY26 EBITDA stood at ₹63.23 crore with a stable margin of 22% for the full year.Major capacity expansion in progress for SteriPort and SVP segments to target domestic and export markets.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the ongoing capacity expansions as they are critical for accelerating revenue growth beyond the current single-digit levels. The significant improvement in earnings quality and reduced finance costs are positive indicators for long-term value creation.
Amanta Healthcare's FY26 presentation highlights a steady 11% Revenue CAGR and a significant financial turnaround, with Debt-to-Equity falling from 3.43x to 1.06x. The company is operating at near-peak capacity with 96% utilization, prompting a ₹130 Cr capex to expand SteriPort and SVP lines by FY27. Management is targeting aggressive growth with a 20%+ Revenue CAGR and 25%+ EBITDA margins over the next two years, supported by efficiency measures like a 10.8 MW solar plant.
முக்கிய அம்சங்கள்
Debt-to-Equity ratio significantly improved from 3.43x in FY23 to 1.06x in FY26 through NCD repayments.SteriPort (LVP) capacity to expand from 6.62 Cr to 11.6 Cr bottles by FY27, targeting ₹110-120 Cr incremental revenue.Total asset utilization reached 96% in FY26, necessitating a ₹130 Cr capex plan for FY26-27.Installation of a 10.8 MW solar captive power plant expected to generate annual cost savings of ₹9 Cr.Management guidance targets 20%+ Revenue CAGR and 25%+ EBITDA margins for the next two fiscal years.
👀 கவனிக்க வேண்டியவை
Investors should monitor the timely commissioning of the new production lines in FY27 and the subsequent margin expansion. The sharp reduction in leverage and high asset utilization suggest a well-managed transition into a high-growth phase.
Amanta Healthcare Promoter Bhavesh Patel Acquires 28,800 Shares via Open Market
Shri Bhavesh Patel, the Promoter, Chairman, and Managing Director of Amanta Healthcare, has purchased 28,800 equity shares of the company. These transactions were conducted through the open market on March 27 and March 30, 2026. The disclosure was made in compliance with SEBI (Prohibition of Insider Trading) Regulations. Such insider buying by the top-most executive is generally perceived as a strong signal of confidence in the company's future performance and valuation.
முக்கிய அம்சங்கள்
Promoter and CMD Shri Bhavesh Patel acquired 28,800 equity shares from the open market.The acquisition took place across two trading sessions on March 27 and March 30, 2026.Disclosure filed under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.The purchase reflects management's direct financial commitment to the company's growth trajectory.
👀 கவனிக்க வேண்டியவை
Investors should take this as a positive cue regarding the company's internal outlook. It is advisable to monitor if the promoter continues to increase their stake in subsequent quarters.
Amanta Healthcare Promoter Bhavesh Patel Acquires 48,151 Shares via Open Market
Shri Bhavesh Patel, a promoter of Amanta Healthcare Limited, has increased his stake by purchasing 48,151 equity shares from the open market. The acquisition took place over two trading sessions on February 26 and February 27, 2026. This transaction was disclosed under the SEBI (Prohibition of Insider Trading) Regulations, 2015. Such insider buying typically signals strong promoter confidence in the company's future prospects and intrinsic value.
முக்கிய அம்சங்கள்
Promoter Shri Bhavesh Patel purchased a total of 48,151 equity shares.The acquisition was conducted through open market transactions on February 26 and 27, 2026.The disclosure was filed in compliance with Regulation 7(2) of SEBI Insider Trading rules.The move indicates increased 'skin in the game' by the promoter group.
👀 கவனிக்க வேண்டியவை
Investors should view this promoter buying as a positive sign of internal confidence, though it should be weighed against the company's overall financial performance.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
